Literature DB >> 6446278

Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders.

N V Manyam, L Katz, T A Hare, J C Gerber, M H Grossman.   

Abstract

Levels of gamma-aminobutyric acid (GABA) in CSF were measured by the ion exchange-fluorometric method in 136 patients who underwent evaluation for neurologic disorders. In 19 patients with no organic neurologic or mental disorders who acted as normal controls, the mean (+/-SD) GABA level in CSF was 239 +/- 76 picomoles/mL. Patients with acute hypoxic encephalopathy showed a mean GABA level in CSF higher than that of the controls, a difference that was statistically significant. In all the other disorders studied, the mean GABA level in CSF was either equal to or lower than that found in the controls. Statistically significant reductions of the GABA level in CSF were seen in patients with Huntington's disease, dementias, cerebellar cortical atrophy, multiple sclerosis, epilepsy, and Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6446278     DOI: 10.1001/archneur.1980.00500550054006

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  30 in total

1.  Free-GABA levels in the cerebrospinal fluid of patients suffering from several neurological diseases Its potential use for the diagnosis of diseases which course with inflammation and tissular necrosis.

Authors:  A T Zepeda; F J Ortiz Nesme; J Méndez-Franco; E Otero-Siliceo; M Pérez de la Mora
Journal:  Amino Acids       Date:  1995-09       Impact factor: 3.520

2.  Evidence for an in vivo and in vitro modulation of endogenous cortical GABA release by alpha-glycerylphosphorylcholine.

Authors:  L Ferraro; S Tanganelli; L Marani; C Bianchi; L Beani; A Siniscalchi
Journal:  Neurochem Res       Date:  1996-05       Impact factor: 3.996

Review 3.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

4.  Increased GFAp levels in CSF as a marker of organicity in patients with Alzheimer's disease and other types of irreversible chronic organic brain syndrome.

Authors:  R Crols; J Saerens; M Noppe; A Lowenthal
Journal:  J Neurol       Date:  1986-06       Impact factor: 4.849

Review 5.  The current state of research with peripheral tissues in Huntington disease.

Authors:  G C Beverstock
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

6.  Effects of GABA, glycine, and sodium barbiturate on dendritic growth in vitro.

Authors:  S J Baloyannis; K Karakatsanis; J Karathanasis; M Apostolakis; A Diacoyannis
Journal:  Acta Neuropathol       Date:  1983       Impact factor: 17.088

7.  Anti-convulsant characteristics of the hydroxamic acid of GABA.

Authors:  H Kehl; K Fountain
Journal:  Naturwissenschaften       Date:  1982-03

8.  Some ethical problems in Huntington's chorea.

Authors:  T L Perry
Journal:  Can Med Assoc J       Date:  1981-11-15       Impact factor: 8.262

Review 9.  GABAergic mechanisms in the pathogenesis and treatment of epilepsy.

Authors:  B S Meldrum
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

10.  Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases.

Authors:  H Kuroda; N Ogawa; Y Yamawaki; I Nukina; T Ofuji; M Yamamoto; S Otsuki
Journal:  J Neurol Neurosurg Psychiatry       Date:  1982-03       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.